ONC Stock Analysis: Buy, Sell, or Hold?
ONC - BeOne Medicines Ltd. American Depositary Shares
$303.96
5.26 (1.76%)
▲
5d:
-1.78%
30d:
+15.31%
90d:
-1.84%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
21d
Get Alerted When ONC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ONC shows positive signals but monitor for confirmation. Market pricing in 6.2% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ONC shows positive signals but monitor for confirmation. Market pricing in 6.2% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$473.88
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$294.25
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ONC is currently trading at $303.96, which is considered extended relative to its 30-day fair value range of $265.69 to $296.75. From a valuation perspective, the stock is trading at a discount (Forward PE: 31.2) compared to its historical average (37.9). Remarkably, the market is currently pricing in an annual earnings decline of 6.2% over the next few years. This pessimistic expectation contrasts with the company's recent 16970.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ONC is in a downtrend. Immediate support is located at $283.07, while resistance sits at $316.00.
Market Sentiment: ONC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $412.53 (+35.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ONC is in a downtrend. Immediate support is located at $283.07, while resistance sits at $316.00.
Market Sentiment: ONC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $412.53 (+35.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$265.69 -
$296.75
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 35.7% below Wall St target ($412.53)
Trading Range Analysis
30-Day Trading Range
$265.69 -
$296.75
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$283.07
Resistance Level
$316.00
Current Trend
Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
31.23
Wall Street Target
$412.53
(+35.7%)
Revenue Growth (YoY)
35.5%
Earnings Growth (YoY)
16970.8%
Profit Margin
8.9%
Valuation Discount vs History
-6.2% cheaper
PE vs Historical
31.2 vs 37.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.2%
(market-implied from PE analysis)
1-Year Target
$285.11
(-6%)
2-Year Target
$267.44
(-12%)
3-Year Target
$250.86
(-18%)
3-Yr Target (if PE normalizes)
(PE: 31→38)
$304.46
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 31.2, Growth: 51.4%)
$1025.86
(+238%)
Base:
(SPY PE: 21.8, Growth: 51.4%)
$715.51
(+135%)
Bear:
(PE: 18.5, Growth: 51.4%)
$608.19
(+100%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (45x PE), but valuation improves significantly next year (31x PE) as earnings recover.
Forward PE: 45.25 | Forward EPS (Implied): $6.72
Bull Case
$367.03
(+21%)
Analyst growth 15.0%, PE expands to 47.5
Base Case
$303.96
(0%)
Market implied 0.0%, PE stable at 45.3
Bear Case
$232.53
(-24%)
Severe decline -15.0%, PE contracts to 40.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 31.2 to 37.9
Stabilization Target:
$368.91
(+21.4%)
PE Expansion Potential:
+21.4%
Share & Embed Analysis
Last updated: July 13, 2026 7:24 PM ET
Data refreshes hourly during market hours. Next update: 8:24 PM
Data refreshes hourly during market hours. Next update: 8:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Chan Henry Lee
SELL
332 shares
2026-04-08
Chan Henry Lee
SELL
341 shares
2026-03-11
Chan Henry Lee
SELL
1660 shares
2026-02-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 59 HOLD |